Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse - PubMed (original) (raw)
Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse
Antonio Abbate et al. Eur J Heart Fail. 2010 Apr.
Free article
No abstract available
Similar articles
- Targeting interleukin-1 in heart failure and inflammatory heart disease.
Van Tassell BW, Raleigh JM, Abbate A. Van Tassell BW, et al. Curr Heart Fail Rep. 2015 Feb;12(1):33-41. doi: 10.1007/s11897-014-0231-7. Curr Heart Fail Rep. 2015. PMID: 25315037 Review. - Antiarrhythmic effects of interleukin 1 inhibition after myocardial infarction.
De Jesus NM, Wang L, Lai J, Rigor RR, Francis Stuart SD, Bers DM, Lindsey ML, Ripplinger CM. De Jesus NM, et al. Heart Rhythm. 2017 May;14(5):727-736. doi: 10.1016/j.hrthm.2017.01.027. Epub 2017 Jan 19. Heart Rhythm. 2017. PMID: 28111350 Free PMC article. - Increased interleukin-1β levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Ørn S, Ueland T, Manhenke C, Sandanger Ø, Godang K, Yndestad A, Mollnes TE, Dickstein K, Aukrust P. Ørn S, et al. J Intern Med. 2012 Sep;272(3):267-76. doi: 10.1111/j.1365-2796.2012.02517.x. Epub 2012 Feb 26. J Intern Med. 2012. PMID: 22243053 - Limiting adverse cardiac remodeling after acute myocardial infarction by blocking interleukin-1.
Guntheroth WG. Guntheroth WG. Am J Cardiol. 2010 Aug 15;106(4):602. doi: 10.1016/j.amjcard.2010.06.004. Am J Cardiol. 2010. PMID: 20691327 No abstract available. - Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?
Nigrovic PA. Nigrovic PA. Arthritis Rheumatol. 2014 Jun;66(6):1405-13. doi: 10.1002/art.38615. Arthritis Rheumatol. 2014. PMID: 24623686 Review. No abstract available.
Cited by
- Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer.
Dinarello CA, Fossati G, Mascagni P. Dinarello CA, et al. Mol Med. 2011 May-Jun;17(5-6):333-52. doi: 10.2119/molmed.2011.00116. Epub 2011 May 5. Mol Med. 2011. PMID: 21556484 Free PMC article. - Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse.
Abbate A, Salloum FN, Van Tassell BW, Vecile E, Toldo S, Seropian I, Mezzaroma E, Dobrina A. Abbate A, et al. PLoS One. 2011;6(11):e27923. doi: 10.1371/journal.pone.0027923. Epub 2011 Nov 28. PLoS One. 2011. PMID: 22140485 Free PMC article. - Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study.
Van Tassell B, Mihalick V, Thomas G, Marawan A, Talasaz AH, Lu J, Kang L, Ladd A, Damonte JI, Dixon DL, Markley R, Turlington J, Federmann E, Del Buono MG, Biondi-Zoccai G, Canada JM, Arena R, Abbate A. Van Tassell B, et al. J Transl Med. 2022 Jun 15;20(1):270. doi: 10.1186/s12967-022-03466-9. J Transl Med. 2022. PMID: 35706006 Free PMC article. Clinical Trial. - Interaction between interleukin-1 beta and angiotensin II receptor 1 in hypothalamic paraventricular nucleus contributes to progression of heart failure.
Liu Q, Wang T, Yu H, Liu B, Jia R. Liu Q, et al. J Interferon Cytokine Res. 2014 Nov;34(11):870-5. doi: 10.1089/jir.2013.0159. Epub 2014 Jun 23. J Interferon Cytokine Res. 2014. PMID: 24955935 Free PMC article. - Targeting interleukin-1 in heart failure and inflammatory heart disease.
Van Tassell BW, Raleigh JM, Abbate A. Van Tassell BW, et al. Curr Heart Fail Rep. 2015 Feb;12(1):33-41. doi: 10.1007/s11897-014-0231-7. Curr Heart Fail Rep. 2015. PMID: 25315037 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical